ORX — Orexo AB Share News
0.000.00%
Last trade - 00:00- SEK850.39m
- SEK471.19m
- SEK26.00m
Brief: Orexo To Launch Second Pharma Product In U.S Late 2024 Or Early 2025
Brief: Orexo Q3 EBIT SEK -28.6 Million
Brief: Orexo Posts Data From Modia Study On Impact On Use Of Illicit Opioids
Brief: Orexo Submits New Drug Application To FDA For Ox124
Brief: Orexo Secures Patent Protection In U.S. For Ox640
Brief: Orexo's Patent Win For Zubsolv Appealed
Brief: Orexo Expects Reduced Opex In H2 Compared To H1
Brief: Orexo Q2 EBIT SEK -12.9 Million
Brief: Orexo Wins Patent Litigation For Zubsolv® In The Us
Brief: Orexo Q1 EPS at SEK -1.86
Brief: Orexo AB It Was Resolved, In Accordance With Board Of Directors' Proposal, That There Shall Be No Dividend For 2022
Brief: Orexo Announced New Timeline For OX124
Brief: Orexo Postpones Publication Of The Annual Report
Brief: Orexo Submits New Drug Application To FDA For OX124, High-Dose Rescue Medication For Opioid Overdose
Brief: Orexo AB Q4 Revenues Rise To SEK 156.1 Million
Brief: Orexo Q4 Revenue Falls Short of Estimates
Brief: Orexo Initiates Feasibility Studies Of Amorphox
Brief: Orexo Q3 EBITDA Loss SEK Narrows To 32.4 Million
Brief: Orexo Announces Positive Data From Phase 1 Clinical Study For OX640